Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASENSUS SURGICAL, INC.ASXC · Entity 88098 | Director | June 30, 2021 | July 02, 2021 |
| Cocrystal Pharma, Inc.COCP · Entity 7621 | Director | September 21, 2018 | September 24, 2018 |
| NON INVASIVE MONITORING SYSTEMS INC /FL/NIMU · Entity 7976 | Director · Interim CEO · 10% owner | December 21, 2018 | December 28, 2018 |
| OPKO HEALTH, INC.OPK · Entity 4891 | Director · Vice Chairman & CTO | May 27, 2025 | May 29, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASENSUS SURGICAL, INC.
Report date June 30, 2021 · Filed July 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 336,895 |
Reported balance
After 2021-07-01 transaction · row 1
1 source rowRow 1 · 2021-07-01 · Grant · Acquired 29,231 · Balance 336,895 F1: Represents restricted stock units ("RSUs"). Each RSU represents the right to receive one share of the Registrant's common stock. F2: Forfeiture restrictions will lapse on the RSUs on the first anniversary of the date of grant, provided that if the date of the 2022 annual meeting of stockholders is earlier, the restrictions will lapse on the date of the annual meeting. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.17 · Expires 2028-06-30 | Direct | 3,748 |
Reported balance
After 2021-06-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-06-30 · Grant · Acquired 3,748 · Balance 3,748 F4: Represents an equity award issued under the Registrant's Amended and Restated Incentive Compensation Plan in lieu of an annual cash retainer, paid quarterly in arrears for the quarter ended June 30, 2021. F5: The award is fully exercisable six months after the grant date, subject to earlier acceleration as approved by the Board of Directors. |
| Common StockSEC Table I · non-derivative | IndirectHsu Gamma Investments, L.P. | 96,746 |
Reported balance
Holding disclosure · report date 2021-06-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 96,746 F3: The Reporting Person is the general partner of Hsu Gama Investments, LP. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"). Each RSU represents the right to receive one share of the Registrant's common stock.
F2: Forfeiture restrictions will lapse on the RSUs on the first anniversary of the date of grant, provided that if the date of the 2022 annual meeting of stockholders is earlier, the restrictions will lapse on the date of the annual meeting.
F3: The Reporting Person is the general partner of Hsu Gama Investments, LP.
F4: Represents an equity award issued under the Registrant's Amended and Restated Incentive Compensation Plan in lieu of an annual cash retainer, paid quarterly in arrears for the quarter ended June 30, 2021.
F5: The award is fully exercisable six months after the grant date, subject to earlier acceleration as approved by the Board of Directors.
Cocrystal Pharma, Inc.
Report date September 21, 2018 · Filed September 24, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.78 · Expires 2028-09-20 | Direct | 50,000 |
Reported balance
After 2018-09-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-09-21 · Grant · Acquired 50,000 · Balance 50,000 F1: The stock options vest as follows: 1/4 will vest on the one year anniversary of the grant date and the remaining 3/4 will vest in 12 equal quarterly increments. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest as follows: 1/4 will vest on the one year anniversary of the grant date and the remaining 3/4 will vest in 12 equal quarterly increments.
NON INVASIVE MONITORING SYSTEMS INC /FL/
Report date December 21, 2018 · Filed December 28, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par value per shareSEC Table I · non-derivative | Direct | 16,752,074 |
Ending reported balance
After 2018-12-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-12-21 · Purchase · Acquired 1,428,571 · Balance 11,828,571 Row 2 · 2018-12-21 · Purchase · Acquired 4,923,503 · Balance 16,752,074 F1: Shares acquired in exchange for indebtedness owed by Non-Invasive Monitoring Systems, Inc. to the reporting person or affiliates thereof. |
| Common Stock, $0.01 par value per shareSEC Table I · non-derivative | IndirectSee Footnote | 20,883,660 |
Reported balance
After 2018-12-21 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2018-12-21 · Purchase · Acquired 20,883,660 · Balance 20,883,660 F1: Shares acquired in exchange for indebtedness owed by Non-Invasive Monitoring Systems, Inc. to the reporting person or affiliates thereof. F2: Held by Hsu Gamma Investments LP, of which the reporting person is the general partner. The reporting person disclaims beneficial ownership of all shares held by Hsu Gamma Investments, LP except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired in exchange for indebtedness owed by Non-Invasive Monitoring Systems, Inc. to the reporting person or affiliates thereof.
F2: Held by Hsu Gamma Investments LP, of which the reporting person is the general partner. The reporting person disclaims beneficial ownership of all shares held by Hsu Gamma Investments, LP except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
OPKO HEALTH, INC.
Report date May 27, 2025 · Filed May 29, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.31 · Expires 2035-05-26 | Direct | 500,000 |
Reported balance
After 2025-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-27 · Grant · Acquired 500,000 · Balance 500,000 F1: This option will vest in four equal annual installments beginning May 27, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest in four equal annual installments beginning May 27, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2025 Filed May 29, 2025 21:07 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0000950170-25-079120 · ownership.xml · derivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2035-05-26 F1 · derivative.exercise_date: This option will vest in four equal annual installments beginning May 27, 2026. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 23:18 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | GrantCommon Stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-087039 · ownership.xml · nonDerivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,499,880 F1 · security: Each restricted stock unit represents a contingent right to receive one share of OPKO common stock upon the vesting of the award. The restricted stock units vest 50% on the second anniversary of the grant date, then 25% on each of the following two years. Read SEC document |
| January 17, 2024 Filed Jan 17, 2024 22:09 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 150,000 | $0.95 | $142,500.00 |
DisclosureSEC source: 0000950170-24-005070 · ownership.xml · nonDerivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,999,880 Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 14:10 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 150,010 | $0.87 | $130,898.73 |
DisclosureSEC source: 0000950170-24-002743 · ownership.xml · nonDerivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,849,880 Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 14:10 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | Grant3.75% Convertible Notes due 2029 · Derivative | Not disclosed | Not disclosed Strike: $1.15 | $6,452,000.00 |
DisclosureSEC source: 0000950170-24-002743 · ownership.xml · derivative · entry 4 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · Not disclosed shares Expires 2029-01-15 F4 · price: The reporting person entered into a Convertible Note Purchase Agreement with OPKO Health, Inc. (the "Issuer") on January 4, 2024, pursuant to which the reporting person disposed of $5,000,000 aggregate principal amount of 5% Convertible Promissory Notes due 2025, and accrued and unpaid interest thereon, in exchange for $6,452,000 aggregate principal amount of the Issuer's 3.75% Convertible Senior Notes due 2029 in a private placement. F3 · derivative.exercise_date: Prior to September 15, 2028, holders of the 3.75% Convertible Senior Notes due 2029 will have the right to convert such notes only in certain circumstances and during specified periods and thereafter, will be convertible at the option of the holder at any time prior to the close of business on the business day immediately preceding January 15, 2029, the maturity date. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 14:10 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | Disposition to issuer5% Convertible Notes due 2025 · Derivative | Not disclosed | Not disclosed Strike: $1.66 | $5,000,000.00 |
DisclosureSEC source: 0000950170-24-002743 · ownership.xml · derivative · entry 3 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · Not disclosed shares Expires 2025-01-31 F2 · price: The 5% Convertible Promissory Notes due 2025 were originally entered into on February 27, 2018 and the Reporting Person had the option to convert all or any portion of the outstanding principal balance of such original notes, plus unpaid interest, into shares of the Issuer's (as defined below) common stock, par value $0.01 per share, at a conversion price of $5.00 per share, at any time prior to the maturity date, which was February 27, 2023. Pursuant to an amendment on February 10, 2023, the maturity date was extended to January 31, 2025, which amendment also reset the conversion price to the 10 day volume weighted average price immediately preceding the date of such amendment, plus a 25% conversion premium, or $1.66. F2 · derivative.exercise_date: The 5% Convertible Promissory Notes due 2025 were originally entered into on February 27, 2018 and the Reporting Person had the option to convert all or any portion of the outstanding principal balance of such original notes, plus unpaid interest, into shares of the Issuer's (as defined below) common stock, par value $0.01 per share, at a conversion price of $5.00 per share, at any time prior to the maturity date, which was February 27, 2023. Pursuant to an amendment on February 10, 2023, the maturity date was extended to January 31, 2025, which amendment also reset the conversion price to the 10 day volume weighted average price immediately preceding the date of such amendment, plus a 25% conversion premium, or $1.66. Read SEC document |
| November 10, 2023 Filed Nov 13, 2023 13:21 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 65,942 | $1.27 | $83,746.34 |
DisclosureSEC source: 0001209191-23-054918 · doc4.xml · nonDerivative · entry 2 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,699,870 Read SEC document |
| November 10, 2023 Filed Nov 13, 2023 13:21 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 34,058 | $1.26 | $42,913.08 |
DisclosureSEC source: 0001209191-23-054918 · doc4.xml · nonDerivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,633,928 Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:39 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | GrantStock Option (Right to Buy) · Derivative | 800,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001209191-23-031036 · doc4.xml · derivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 800,000 shares Expires 2033-05-17 F1 · derivative.exercise_date: This option will vest in four equal annual installments beginning May 18, 2024. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 23:06 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | Grant5% Convertible Promissory Notes due 2025 · Derivative | Not disclosed | $5,000,000.00 Strike: $1.66 | $5,000,000.00 |
DisclosureSEC source: 0001209191-23-009337 · doc4.xml · derivative · entry 2 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · Not disclosed shares Expires 2025-01-31 F1 · kind: The two reported transactions involved an amendment and restatement of an outstanding convertible promissory note (the "Original Note"), resulting in the deemed cancellation of the Original Note and the execution of an amended note (the "Amended Note"). The Original Note was entered into on February 27, 2018 and the Reporting Person had the option to convert all or any portion of the outstanding principal balance of the Original Note, plus unpaid interest, into shares of the Issuer's common stock, par value $0.01 per share, at a conversion price of $5.00 per share, at any time prior to the maturity date, which was February 27, 2023. The Amended Note extends the maturity to January 31, 2025, and resets the conversion price to the 10 day volume weighted average price immediately preceding the date of the Amended Note, plus a 25% conversion premium, or $1.66. F1 · derivative.exercise_date: The two reported transactions involved an amendment and restatement of an outstanding convertible promissory note (the "Original Note"), resulting in the deemed cancellation of the Original Note and the execution of an amended note (the "Amended Note"). The Original Note was entered into on February 27, 2018 and the Reporting Person had the option to convert all or any portion of the outstanding principal balance of the Original Note, plus unpaid interest, into shares of the Issuer's common stock, par value $0.01 per share, at a conversion price of $5.00 per share, at any time prior to the maturity date, which was February 27, 2023. The Amended Note extends the maturity to January 31, 2025, and resets the conversion price to the 10 day volume weighted average price immediately preceding the date of the Amended Note, plus a 25% conversion premium, or $1.66. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 23:06 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | Disposition to issuer5% Convertible Promissory Notes due 2023 · Derivative | Not disclosed | $5,000,000.00 Strike: $5.00 | $5,000,000.00 |
DisclosureSEC source: 0001209191-23-009337 · doc4.xml · derivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · Not disclosed shares Expires 2023-02-27 F1 · kind: The two reported transactions involved an amendment and restatement of an outstanding convertible promissory note (the "Original Note"), resulting in the deemed cancellation of the Original Note and the execution of an amended note (the "Amended Note"). The Original Note was entered into on February 27, 2018 and the Reporting Person had the option to convert all or any portion of the outstanding principal balance of the Original Note, plus unpaid interest, into shares of the Issuer's common stock, par value $0.01 per share, at a conversion price of $5.00 per share, at any time prior to the maturity date, which was February 27, 2023. The Amended Note extends the maturity to January 31, 2025, and resets the conversion price to the 10 day volume weighted average price immediately preceding the date of the Amended Note, plus a 25% conversion premium, or $1.66. F1 · derivative.exercise_date: The two reported transactions involved an amendment and restatement of an outstanding convertible promissory note (the "Original Note"), resulting in the deemed cancellation of the Original Note and the execution of an amended note (the "Amended Note"). The Original Note was entered into on February 27, 2018 and the Reporting Person had the option to convert all or any portion of the outstanding principal balance of the Original Note, plus unpaid interest, into shares of the Issuer's common stock, par value $0.01 per share, at a conversion price of $5.00 per share, at any time prior to the maturity date, which was February 27, 2023. The Amended Note extends the maturity to January 31, 2025, and resets the conversion price to the 10 day volume weighted average price immediately preceding the date of the Amended Note, plus a 25% conversion premium, or $1.66. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 20:12 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 10 | $3.73 | $37.30 |
DisclosureSEC source: 0001209191-21-050591 · doc4.xml · nonDerivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,599,870 F1 · balance_after: Includes 3,124,713 shares received as a pro rata distribution from The Frost Group, LLC ("The Frost Group"), of which the reporting person was a member. The Frost Group effected a pro rata distribution of its 20,091,062 shares of the Issuer, pursuant to which the reporting person now has direct beneficial ownership of her pro rata share of the securities formerly held by The Frost Group. The reporting person previously reported that the shares were owned directly by The Frost Group. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 19:06 UTC | ASENSUS SURGICAL, INC. ASXC · Entity 88098 | GrantCommon Stock | 29,231 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-045178 · doc4.xml · nonDerivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,895 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the right to receive one share of the Registrant's common stock. F2 · shares: Forfeiture restrictions will lapse on the RSUs on the first anniversary of the date of grant, provided that if the date of the 2022 annual meeting of stockholders is earlier, the restrictions will lapse on the date of the annual meeting. F1 · price: Represents restricted stock units ("RSUs"). Each RSU represents the right to receive one share of the Registrant's common stock. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 19:06 UTC | ASENSUS SURGICAL, INC. ASXC · Entity 88098 | GrantStock Option · Derivative | 3,748 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0001209191-21-045178 · doc4.xml · derivative · entry 3 HSIAO JANE PH D · CIK 0001188834 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,748 Underlying: Common Stock · 3,748 shares Expires 2028-06-30 F4 · security: Represents an equity award issued under the Registrant's Amended and Restated Incentive Compensation Plan in lieu of an annual cash retainer, paid quarterly in arrears for the quarter ended June 30, 2021. F5 · derivative.exercise_date: The award is fully exercisable six months after the grant date, subject to earlier acceleration as approved by the Board of Directors. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 18:15 UTC | ASENSUS SURGICAL, INC. ASXC · Entity 88098 | GrantStock Option · Derivative | 3,155 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001209191-21-024776 · doc4.xml · derivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,155 Underlying: Common Stock · 3,155 shares Expires 2028-03-31 F1 · security: Represents an equity award issued under the Registrant's Amended and Restated Incentive Compensation Plan in lieu of an annual cash retainer, paid quarterly in arrears for the quarter ended March 31, 2021. F2 · derivative.exercise_date: The award is fully exercisable six months after the grant date, subject to earlier acceleration as approved by the Board of Directors. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 21:08 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001209191-21-012667 · doc4.xml · derivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2031-02-18 F1 · derivative.exercise_date: This option will vest in four equal annual installments beginning February 19, 2022. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 19:10 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantStock Option · Derivative | 12,831 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001209191-21-001611 · doc4.xml · derivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,831 Underlying: Common Stock · 12,831 shares Expires 2028-12-31 F1 · security: Represents an equity award issued under the Registrant's Amended and Restated Incentive Compensation Plan in lieu of an annual cash retainer, paid quarterly in arrears for the quarter ended December 31, 2020. F2 · derivative.exercise_date: The award is fully exercisable six months after the grant date, subject to earlier acceleration as approved by the Board of Directors. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 17:36 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantStock Option · Derivative | 12,915 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001209191-20-053286 · doc4.xml · derivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,915 Underlying: Common Stock · 12,915 shares Expires 2027-09-30 F1 · security: Represents an equity award issued under the Registrant's Amended and Restated Incentive Compensation Plan in lieu of an annual cash retainer, paid quarterly in arrears for the quarter ended September 30, 2020. F2 · derivative.exercise_date: The award is fully exercisable six months after the grant date, subject to earlier acceleration as approved by the Board of Directors. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:53 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantStock Option · Derivative | 31,250 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001209191-20-035741 · doc4.xml · derivative · entry 4 HSIAO JANE PH D · CIK 0001188834 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 31,250 shares Expires 2027-06-08 F4 · derivative.exercise_date: The stock options will vest 25% on each of September 8, 2020, December 8, 2020, March 8, 2021 and June 8, 2021, provided that if the date of the 2021 annual meeting of stockholders is earlier, the last vesting occurs on the date of the annual meeting. Subject to acceleration of vesting in full upon consummation of a change in control of the Registrant. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:53 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantCommon Stock | 22,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-035741 · doc4.xml · nonDerivative · entry 2 HSIAO JANE PH D · CIK 0001188834 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,664 F1 · shares: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock. F2 · shares: The restricted stock units remain subject to forfeiture until the first anniversary of the date of grant or, if earlier, the date of the next annual meeting of stockholders, as long as the Reporting Person remains in continuous service during the vesting period. F1 · price: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:53 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantCommon Stock | 7,988 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-035741 · doc4.xml · nonDerivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,164 F1 · shares: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock. F2 · shares: The restricted stock units remain subject to forfeiture until the first anniversary of the date of grant or, if earlier, the date of the next annual meeting of stockholders, as long as the Reporting Person remains in continuous service during the vesting period. F1 · price: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:15 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | GrantStock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001209191-20-034965 · doc4.xml · derivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2030-06-03 F1 · derivative.exercise_date: This option will vest in four equal annual installments beginning June 4, 2021. Read SEC document |
| October 25, 2019 Filed Oct 25, 2019 18:10 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 400,000 | $1.50 | $600,000.00 |
DisclosureSEC source: 0001209191-19-054066 · doc4.xml · nonDerivative · entry 2 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,127,404 F1 · ownership.nature: The securities are owned directly by Hsu Gamma Investment, L.P. Dr. Hsiao is the general partner of Hsu Gamma Investment, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:05 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001209191-19-040731 · doc4.xml · derivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2029-06-30 F1 · derivative.exercise_date: This option will vest in four equal annual installments beginning July 1, 2020. Read SEC document |
| May 09, 2019 Filed May 10, 2019 10:17 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 2,783 | $2.04 | $5,677.32 |
DisclosureSEC source: 0001209191-19-028670 · doc4.xml · nonDerivative · entry 3 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,475,147 Read SEC document |
| May 09, 2019 Filed May 10, 2019 10:17 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 500 | $2.04 | $1,017.50 |
DisclosureSEC source: 0001209191-19-028670 · doc4.xml · nonDerivative · entry 2 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,472,364 Read SEC document |
| May 09, 2019 Filed May 10, 2019 10:17 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 6,717 | $2.03 | $13,601.93 |
DisclosureSEC source: 0001209191-19-028670 · doc4.xml · nonDerivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,471,864 Read SEC document |
| April 25, 2019 Filed Apr 26, 2019 20:01 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantStock Option Award · Derivative | 29,104 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001209191-19-026316 · doc4.xml · derivative · entry 3 HSIAO JANE PH D · CIK 0001188834 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,104 Underlying: Common Stock · 29,104 shares Expires 2029-04-25 F4 · derivative.exercise_date: The vesting schedule is 25% of the stock option award on July 1, 2019, October 1, 2019, January 1, 2020 and April 1, 2020. Subject to acceleration of vesting in full upon consummation of a change in control of the registrant. Read SEC document |
| April 25, 2019 Filed Apr 26, 2019 20:01 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantCommon Stock | 20,380 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-026316 · doc4.xml · nonDerivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,603,278 F1 · shares: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock. F2 · shares: The restricted stock units remain subject to forfeiture until the first anniversary of the date of grant or, if earlier, the date of the next annual meeting of stockholders, as long as the reporting person remains in continuous service during the vesting period. F1 · price: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock. Read SEC document |
| December 21, 2018 Filed Dec 28, 2018 00:36 UTC | NON INVASIVE MONITORING SYSTEMS INC /FL/ NIMU · Entity 7976 | PurchaseCommon Stock, $0.01 par value per share | 20,883,660 | $0.07 | $1,461,856.20 |
DisclosureSEC source: 0001493152-18-018021 · ownership.xml · nonDerivative · entry 3 HSIAO JANE PH D · CIK 0001188834 · Director · Interim CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 20,883,660 F1 · shares: Shares acquired in exchange for indebtedness owed by Non-Invasive Monitoring Systems, Inc. to the reporting person or affiliates thereof. F1 · price: Shares acquired in exchange for indebtedness owed by Non-Invasive Monitoring Systems, Inc. to the reporting person or affiliates thereof. F2 · ownership.nature: Held by Hsu Gamma Investments LP, of which the reporting person is the general partner. The reporting person disclaims beneficial ownership of all shares held by Hsu Gamma Investments, LP except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 21, 2018 Filed Dec 28, 2018 00:36 UTC | NON INVASIVE MONITORING SYSTEMS INC /FL/ NIMU · Entity 7976 | PurchaseCommon Stock, $0.01 par value per share | 4,923,503 | $0.07 | $344,645.21 |
DisclosureSEC source: 0001493152-18-018021 · ownership.xml · nonDerivative · entry 2 HSIAO JANE PH D · CIK 0001188834 · Director · Interim CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,752,074 F1 · shares: Shares acquired in exchange for indebtedness owed by Non-Invasive Monitoring Systems, Inc. to the reporting person or affiliates thereof. F1 · price: Shares acquired in exchange for indebtedness owed by Non-Invasive Monitoring Systems, Inc. to the reporting person or affiliates thereof. Read SEC document |
| December 21, 2018 Filed Dec 28, 2018 00:36 UTC | NON INVASIVE MONITORING SYSTEMS INC /FL/ NIMU · Entity 7976 | PurchaseCommon Stock, $0.01 par value per share | 1,428,571 | $0.07 | $99,999.97 |
DisclosureSEC source: 0001493152-18-018021 · ownership.xml · nonDerivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director · Interim CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,828,571 Read SEC document |
| December 13, 2018 Filed Feb 5, 2019 21:31 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | GiftCommon Stock | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-007347 · doc4.xml · nonDerivative · entry 6 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F3 · ownership.nature: The securities are held by The Chin Hsiao Family Trust B, of which Jane H. Hsiao, Ph.D. is the trustee. Read SEC document |
| December 13, 2018 Filed Feb 5, 2019 21:31 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | GiftCommon Stock | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-007347 · doc4.xml · nonDerivative · entry 5 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F2 · ownership.nature: The securities are held by The Chin Hsiao Family Trust A, of which Jane H. Hsiao, Ph.D. is the trustee. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 12:42 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | GrantCommon Stock | 573,066 | $3.49 | $2,000,000.34 |
DisclosureSEC source: 0001209191-18-058057 · doc4.xml · nonDerivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,346,199 Read SEC document |
| September 21, 2018 Filed Sep 24, 2018 20:56 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001493152-18-013674 · ownership.xml · derivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-09-20 F1 · derivative.exercise_date: The stock options vest as follows: 1/4 will vest on the one year anniversary of the grant date and the remaining 3/4 will vest in 12 equal quarterly increments. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 20:12 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $4.46 | $0.00 |
DisclosureSEC source: 0001209191-18-039168 · doc4.xml · derivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2028-06-20 F1 · derivative.exercise_date: The options were granted on June 21, 2018 and vest annually in four equal installments beginning on June 21, 2019. Read SEC document |
| May 24, 2018 Filed May 29, 2018 06:59 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantStock Option Award · Derivative | 35,592 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0001209191-18-033656 · doc4.xml · derivative · entry 3 HSIAO JANE PH D · CIK 0001188834 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,592 Underlying: Common Stock · 35,592 shares Expires 2028-05-24 F4 · derivative.exercise_date: The vesting schedule is 25% of the stock option award on each of July 1, 2018, October 1, 2018, January 1, 2019 and April 1, 2019. Read SEC document |
| May 24, 2018 Filed May 29, 2018 06:59 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantCommon Stock | 20,362 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-033656 · doc4.xml · nonDerivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,582,898 F1 · security: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock. F1 · price: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock. F2 · price: The restricted stock units remain subject to forfeiture until the first anniversary of the date of grant or, if earlier, the date of the next annual meeting of stockholders, as long as the reporting person remains in continuous service during the vesting period. Read SEC document |
| March 22, 2018 Filed Mar 26, 2018 08:30 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | OtherWarrants · Derivative | 400,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001209191-18-021583 · doc4.xml · derivative · entry 3 HSIAO JANE PH D · CIK 0001188834 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,000 shares Expires 2018-03-22 F1 · kind: On March 22, 2018, the reporting person exercised warrants to purchase 400,000 shares of common stock of TransEnterix, Inc., par value $0.001 per share, for a purchase price of $1.65 per share. Read SEC document |
| March 22, 2018 Filed Mar 26, 2018 08:30 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | OtherCommon Stock | 400,000 | $1.65 | $660,000.00 |
DisclosureSEC source: 0001209191-18-021583 · doc4.xml · nonDerivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,562,536 F1 · kind: On March 22, 2018, the reporting person exercised warrants to purchase 400,000 shares of common stock of TransEnterix, Inc., par value $0.001 per share, for a purchase price of $1.65 per share. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 21:10 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | Grant5% Convertible Promissory Note · Derivative | Not disclosed | $5,000,000.00 Strike: $5.00 | $5,000,000.00 |
DisclosureSEC source: 0001209191-18-014956 · doc4.xml · derivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 1,000,000 shares Expires 2023-02-27 F1 · derivative.exercise_price: The Reporting Person has the option, from time to time, to convert all or any portion of the outstanding principal balance of the 5% Convertible Promissory Note (the "Note"), together with accrued and unpaid interest thereon, into shares of the Issuer's common stock, par value $0.01 per share ("Common Stock"), at a conversion price of $5.00 per share of Common Stock. F2 · derivative.exercise_date: The Note may be converted at any time prior to the Maturity Date. F3 · derivative.expiration_date: The Notes will mature on February 27, 2023, unless repurchased, redeemed or converted prior to such date. F4 · derivative.underlying_shares: Based on the principal amount of the Note, excluding shares issuable upon conversion of accrued and unpaid interest as of the date of conversion. F4 · valueOwnedAfter: Based on the principal amount of the Note, excluding shares issuable upon conversion of accrued and unpaid interest as of the date of conversion. Read SEC document |
| May 25, 2017 Filed May 26, 2017 16:17 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantStock Option Award · Derivative | 20,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001209191-17-035807 · doc4.xml · derivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-25 F1 · derivative.exercise_date: Vests 25% per quarter on each quarterly anniversary of the date of grant with the final vesting on the first anniversary of the date of grant. Read SEC document |
| May 11, 2017 Filed May 12, 2017 14:53 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 10,000 | $6.93 | $69,300.00 |
DisclosureSEC source: 0001209191-17-031741 · doc4.xml · nonDerivative · entry 2 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,773,133 Read SEC document |
| May 11, 2017 Filed May 12, 2017 14:53 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 10,000 | $6.92 | $69,200.00 |
DisclosureSEC source: 0001209191-17-031741 · doc4.xml · nonDerivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,763,133 Read SEC document |
| May 11, 2017 Filed Feb 5, 2019 21:30 UTC Amendment | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 10,000 | $6.93 | $69,300.00 |
DisclosureSEC source: 0001209191-19-007346 · doc4a.xml · nonDerivative · entry 2 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,677,404 F1 · date: The securities were erroneously reported as being purchased by the reporting person and owned directly on a Form 4 filed on May 12, 2017. The securities were purchased by Hsu Gamma Investment, L.P. and are owned indirectly by the reporting person. This Form 4 corrects the name and ownership of the securities. No other information has changed. F1 · kind: The securities were erroneously reported as being purchased by the reporting person and owned directly on a Form 4 filed on May 12, 2017. The securities were purchased by Hsu Gamma Investment, L.P. and are owned indirectly by the reporting person. This Form 4 corrects the name and ownership of the securities. No other information has changed. F2 · ownership.nature: The securities are owned directly by Hsu Gamma Investment, L.P. Dr. Hsiao is the general partner of Hsu Gamma Investment, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 11, 2017 Filed Feb 5, 2019 21:30 UTC Amendment | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 10,000 | $6.92 | $69,200.00 |
DisclosureSEC source: 0001209191-19-007346 · doc4a.xml · nonDerivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,667,404 F1 · date: The securities were erroneously reported as being purchased by the reporting person and owned directly on a Form 4 filed on May 12, 2017. The securities were purchased by Hsu Gamma Investment, L.P. and are owned indirectly by the reporting person. This Form 4 corrects the name and ownership of the securities. No other information has changed. F1 · kind: The securities were erroneously reported as being purchased by the reporting person and owned directly on a Form 4 filed on May 12, 2017. The securities were purchased by Hsu Gamma Investment, L.P. and are owned indirectly by the reporting person. This Form 4 corrects the name and ownership of the securities. No other information has changed. F2 · ownership.nature: The securities are owned directly by Hsu Gamma Investment, L.P. Dr. Hsiao is the general partner of Hsu Gamma Investment, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 10, 2017 Filed May 11, 2017 10:50 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 10,000 | $6.99 | $69,900.00 |
DisclosureSEC source: 0001209191-17-031425 · doc4.xml · nonDerivative · entry 5 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,753,133 Read SEC document |
| May 10, 2017 Filed May 11, 2017 10:50 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 5,665 | $6.98 | $39,541.70 |
DisclosureSEC source: 0001209191-17-031425 · doc4.xml · nonDerivative · entry 4 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,743,133 Read SEC document |
| May 10, 2017 Filed May 11, 2017 10:50 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 11,735 | $6.97 | $81,792.95 |
DisclosureSEC source: 0001209191-17-031425 · doc4.xml · nonDerivative · entry 3 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,737,468 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.